Results 161 to 170 of about 15,025,843 (286)

Treatment‐Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of ESSDAI and STAR Response to B Cell Therapy in Sjögren's Disease

Arthritis &Rheumatology, EarlyView.
Graphical Abstract Objective This study aimed to characterize whole blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or B lymphocyte stimulator/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to nonresponse. Methods Whole blood RNA sequencing was performed
Aimen Ibrahim, Junjie Peng, Eileen Tian, Lucia Martin‐Gutierrez, John Casement, Kyle Thompson, Wan‐Fai Ng, André van Maurik, Elizabeth C. Jury, Coziana Ciurtin   +9 more
wiley   +1 more source

A novel subset of T-helper cells: follicular T-helper cells and their markers

Haematologica, 2010
Camille Laurent, Nicolas Fazilleau, Pierre Brousset   +2 more
doaj   +1 more source

Differentiation and Pathological Significance of Tissue‐Resident Memory‐Like CD8+ T Cells in Systemic Lupus Erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Tissue‐resident memory T (TRM) cells have been implicated in organ‐specific immune pathology; however, the pathological relevance of TRM‐like CD8+ T cells in systemic lupus erythematosus (SLE) remains unclear. We investigated their differentiation mechanisms and pathological significance in SLE, including associations with disease activity ...
Yuya Fujita, Kaoru Yamagata, Satoshi Kubo, Ippei Miyagawa, Koshiro Sonomoto, Yurie Satoh‐Kanda, Masanobu Ueno, Shumpei Kosaka, Aya Nawata, Yoshiya Tanaka, Shingo Nakayamada   +10 more
wiley   +1 more source

Synovial Tissue‐Guided Interleukin‐17A Inhibition for Refractory Arthritis in a Patient With Systemic Juvenile Idiopathic Arthritis

Arthritis &Rheumatology, Accepted Article.
Objective The objective of this study was to characterize the clinical, immunologic, and synovial tissue features of a patient with a systemic juvenile idiopathic arthritis (sJIA) who carries a novel heterozygous STAT5B loss‐of‐function variant (p.Gln139Ter) and whose arthritis responded markedly to interleukin‐17A (IL‐17A) inhibition.
Indira Sriram, Tomohiro Kawabe, Hitoshi Irabu, Mariana Correia Marques, Clara Lin, Alisa Gaskell, Jun Inamo, Michael R. Clay, Roselyn Fierkens, Robert C. Fuhlbrigge, Jeremy D. Prager, Norman R. Friedman, Sarah A. Gitomer, Michael J. Ombrello, Kentaro Yomogida   +14 more
wiley   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source

Transfersomes with core and surface‐loaded NF‐κB p65 siRNA for enhanced transdermal transfection and effective treatment of psoriasis

BMEMat, EarlyView.
TCPL, a transfersome with Tween 80 and PEI, enables efficient transdermal siNF‐κB delivery, resolving PEI's toxicity issue. It promotes lysosomal escape and effective transfection, silences NF‐κB, modulates immunity, and inhibits angiogenesis, alleviating psoriasis. With good biocompatibility, TCPL holds strong clinical translation potential. Schematic
Hui Xing, Yuhui Yang, Ziyi Zhao, Kai Lv, Yiran Shao, Zhi Zhang, Dong Ma   +6 more
wiley   +1 more source

Targeting T follicular helper cells for lifelong health. [PDF]

Nat Rev Drug Discov
Linterman MA, Yu D, Webb LMC, Vinuesa CG.   +3 more
europepmc   +1 more source